Modified vaccinia virus ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4955-4963

  Drexler, Ingo ^a,b,c   Antunes, Edite ^e   Schmitz, Marc ^d   Wölfel, Thomas ^e   Huber, Christoph ^e   Erfle, Volker ^a,c   Rieber, Peter ^d   Theobald, Matthias ^e   Sutter, Gerd ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; VACCINIA VACCINE;

ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS;

ANIMALS; CELL LINE; DENDRITIC CELLS; ENZYME INDUCTION; GENETIC MARKERS; GENETIC VECTORS; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, TRANSGENIC; MONOPHENOL MONOOXYGENASE; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; SMALLPOX VACCINE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINIA VIRUS;

EID: 0033215226     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Van den Eynde, B. J., and Van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Kawakami, Y., Robbins, P. F., Wang, R. F., Parkhurst, M., Kang, X. Q., and Rosenberg, S. A. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother., 21: 237-246, 1998.
3. Kittlesen, D. J., Thompson, L. W., Gulden, P. H., Skipper, J. C. A., Colella, T. A., Shabanowitz, J. A., Hunt, D. F., Engelhard, V. H., and Slingluff, C. L. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J. Immunol., 160: 2099-2106, 1998.
4. Yee, C., Gilbert, M. J., Riddell, S. R., Brichard, V. G., Fefer, A., Thompson, J. A., Boon, T., and Greenberg, P. D. Isolation of tyrosinase-specific CD8(+) and CD4(+) T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol., 157: 4079-4086, 1996.
5. Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X. Q., Sakaguchi, K., Appella, E., and Rosenberg, S. A. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J. Immunol., 161: 6985-6992, 1998.
6. Kobayashi, H., Kokubo, T., Sato, K., Kimura, S., Asano, K., Takahashi, H., Iizuka, H., Miyokawa, N., and Katagiri, M. CD4(+) T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res., 58: 296-301, 1998.
7. Chen, Y. T., Stockert, E., Tsang, S., Coplan, K. A., and Old, L. J. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. Natl. Acad. Sci. USA, 92: 8125-8129, 1995.
8. Halaban, R., Cheng, E., Zhang, Y. H., Moellmann, G., Hanlon, D., Michalak, M., Setaluri, V., and Hebert, D. N. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc. Natl. Acad. Sci. USA, 94: 6210-6215, 1997.
9. Cormier, J. N., Abati, A., Fetsch, P., Hijazi, Y. M., Rosenberg, S. A., Marincola, F. M., and Topalian, S. L. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother., 21: 27-31, 1998.
10. Visseren, M. J., Van Elsas, A., Van der Voort, E. I., Ressing, M. E., Kast, W. M., Schrier, P. I., and Melief, C. J. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol., 154: 3991-3998, 1995.
11. Dunbar, P. R., Chen, J. L., Chao, D., Rust, N., Teisserenc, H., Ogg, G. S., Romero, P., Weynants, P., and Cerundolo, V. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol., 162: 6959-6962, 1999.
12. Tief, K., Schmidt, A., and Beermann, F. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Mol. Brain Res., 53: 307-310, 1998.
13. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.
14. Maleckar, J. R., Friddell, C. S., Sferruzza, A., Thurman, G. B., Lewko, W. M., West, W. H., Oldham, R. K., and Yannelli, J. R. Activation and expansion of tumor-derived activated cells for therapeutic use. J. Natl. Cancer Inst., 81: 1655-1660, 1989.
15. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
16. Jager, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., and Knuth, A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CDS(+) cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66: 470-476, 1996.
17. Alexander-Miller, M. A., Leggatt, G. R., and Berzofsky, J. A. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA, 93: 4102-4107, 1996.
18. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. I., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA, 93: 7855-7860, 1996.
19. Zhai, Y., Yang, J. C., Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., Couture, L. A., Smith, A. E., and Rosenberg, S. A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156: 700-710, 1996.
20. Wang, M., Bronte, V., Chen, P. W., Gritz, L., Panicali, D., Rosenberg, S. A., and Restifo, N. P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol., 154: 4685-4692, 1995.
21. Rao, J. B., Chamberlain, R. S., Bronte, V., Carroll, M. W., Irvine, K. R., Moss, B., Rosenberg, S. A., and Restifo, N. P. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol., 156: 3357-3365, 1996.
22. Moss, B. Genetically engineered poxvimses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA, 93: 11341-11348, 1996.
23. Bronte, V., Tsung, K., Rao, J., Chen, P., Wang, M., Rosenberg, S., and Restifo, N. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol., 154: 5282-5292, 1995.
24. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C. L., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
25. Rosenberg, S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst., 88: 1635-1644, 1996.
26. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z., and Ladnyi, I. Smallpox and its eradication. Geneva: WHO, 1988.
27. Mayr, A., Hochstein-Mintzel, V., and Stickl, H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection, 3: 6-14, 1975.
28. Meyer, H., Sutter, G., and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol., 72: 1031-1038, 1991.
29. Sutter, G., Ramsey-Ewing, A., Rosales, R., and Moss, B. Stable expression of the vaccinia virus KIL gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol., 68: 4109-4116, 1994.
30. Drexler, I., Heller, K., Wahren, B., Erfle, V., and Sutter, G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol., 79: 347-352, 1998.
31. Werner, G., Jentzsch, U., Metzger, E., and Simon, J. Studies on poxvirus infections in irradiated animals. Arch. Virol., 64: 247-256, 1980.
32. Sutter, G., and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA, 89: 10847-10851, 1992.
33. Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R., and Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine, 12: 1032-1040, 1994.
34. Nam, J. H., Wyatt, L. S., Chae, S. L., Cho, H. W., Park, Y. K., and Moss, B. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine, 17: 261-268, 1999.
35. Hirsch, V. M., Fuerst, T. R., Sutter, G., Carroll, M. W., Yang, L. C., Goldstein, S., Piatak, M., Elkins, W. R., Alvord, W. G., Montefiori, D. C., Moss, B., and Lifson, J. D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol., 70: 3741-3752, 1996.
36. Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., and Hill, A. V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med., 4: 397-402, 1998.
37. Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenberg, S. A., Moss, B., and Restifo, N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine, 15: 387-394, 1997.
38. Sherman, L. A., Hesse, S. V., Irwin, M. J., La Face, D., and Peterson, P. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science (Washington DC), 258: 815-818, 1992.
39. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyle response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med., 173: 1007-1015, 1991.
40. Skipper, J. C. A., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., Hunt, D. F., and Engelhard, V. H. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med., 183: 527-534, 1996.
41. Morrison, J., Elvin, J., Latron, F., Gotch, F., Moots, R., Strominger, J. L., and McMichael, A. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur. J. Immunol., 22: 903-907, 1992.
42. Jimenez, M., Tsukamoto, K., and Hearing, V. J. Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J. Biol. Chem., 266: 1147-1156, 1991.
43. Salter, R. D., and Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J., 5: 943-949, 1986.
44. Wolfel, T., Hauer, M., Klehmann, E., Brichard, V., Ackermann, B., Knuth, A., Boon, T., and Meyer zum Buschenfelde, K. H. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer, 55: 237-244, 1993.
45. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
46. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
47. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
48. Cella, M., Sallusto, F., and Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 9: 10-16, 1997.
49. Wolfel, T., Schneider, J., Meyer zum Buschenfelde, K. H., Rammensee, H. G., Rotzschke, O., and Falk, K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer, 57: 413-418, 1994.
50. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Nail. Acad. Sci. USA, 92: 11993-11997, 1995.
51. Theobald, M., Biggs, J., Hemandez, J., Lustgarten, J., Labadie, C., and Sherman, L. A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med., 185: 833-841, 1997.
52. Sutter, G., Ohlmann, M., and Erfle, V. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett., 371: 9-12, 1995.
53. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol, 24: 759-764, 1994.
54. Mosse, C. A., Meadows, L., Luckey, C. J., Kittlesen, D. J., Huczko, E. L., Slingluff, C. L., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med., 187: 37-48, 1998.
55. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
56. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
57. Demkowicz, W. E., Littaua, R. A., Wang, J. M., and Ennis, F. A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol., 70: 2627-2631, 1996.
58. Rosenberg, S. A., Zhai, Y. F., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H., Roberts, B., and White, D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst., 90: 1894-1900, 1998.
59. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S., Smith, G. L., and McMichael, A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime MVA boost vaccination regime. Vaccine, 16: 439-445, 1998.